Magnolia Medical Technologies makes a product that aims to reduce the rate of false positive diagnoses of sepsis.
Seattle-based Magnolia Medical Technologies has raised $13.8 million to continue developing a product that aims to provide accurate blood tests.
Magnolia makes the SteriPath blood-collection system, which is meant to decrease the number of false positives for sepsis, a complication of a bloodstream infection that is often treated with antibiotics and can be life-threatening.
Such false positives can mean that patients are given procedures and treatments they don’t need, exposing them to more risk, Magnolia said in a news release announcing the funding. More than 1 million people in the U.S. are misdiagnosed with sepsis each year, the company said.
Menlo Park, Calif.-based HealthQuest Capital led the funding round and announced managing partner Garheng Kong would join Magnolia’s board.
Most Read Stories
- Seahawks, Titans only teams to both not take the field during day of anthem protests across NFL WATCH
- Huskies get first test of season out of the way and they aced it with win at Colorado | Larry Stone
- A daring betrayal helped wipe out Cali cocaine cartel
- Analysis: Three things we learned from the Seahawks' 33-27 loss to the Tennessee Titans
- Pete Carroll responds to Trump comments, backs Seahawks: 'We stand for our players and their constitutional rights'
SteriPath is commercially available, and the company will use the investment to expand the product into hospitals.